Company / Revenue
Anixa Biosciences Inc Revenue History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$210.0K
FY2024
5-year range
$210.0K / $1.1M
FY2020-FY2024
Trend
+0.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 10 years, ranging from $210,000 in FY2024 to $9M in FY2016.
Based on SEC 10-K filings.
$210,000 in FY2024 with a 10-year CAGR of -6.0%.
Declined from $512,000 to $210,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -28.4%
- 10-Year CAGR
- -6.0%
Key checks
Key Insights
- 5-year CAGR of -28.4%, indicating a declining trend.
- In FY2024, revenue increased 0.0% year-over-year.
- Peak revenue was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $210.0K | +0.0% |
| FY2023 | $210.0K | -59.0% |
| FY2022 | $512.0K | +104.8% |
| FY2020 | $250.0K | -77.5% |
| FY2019 | $1.1M | +206.9% |
| FY2018 | $362.5K | +20.8% |
| FY2017 | $300.0K | -96.8% |
| FY2016 | $9.3M | +152.4% |
| FY2015 | $3.7M | +843.1% |
| FY2014 | $388.9K | -61.2% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026